Bayer (BAYN) Corporate presentation summary

Strategic positioning and market outlook

• Positioned as a global leader in health and nutrition, with strong market shares in crop science, pharmaceuticals, and consumer health.

• Expects above-market growth in crop science and significant opportunities in pharmaceuticals and consumer health.

• Focused on innovation to address megatrends such as population growth, aging, and ecosystem pressures.

• Mission centers on health for all and hunger for none, with divisional visions targeting disease treatment, self-care, and regenerative agriculture.

Financial performance and guidance

• 2025 net sales reached €45.6bn, with EBITDA before special items at €9.7bn and core EPS at €4.91.

• Free cash flow declined to €2.1bn in 2025, impacted by higher incentive and litigation payouts.

• Net financial debt reduced to €29.8bn in 2025, reflecting focused capital allocation and FX tailwinds.

• 2026 outlook reiterates guidance for stable sales and EBITDA, with improved net financial debt due to equity investment.

Innovation and R&D

• Annual R&D investments of approximately €6bn support a robust pipeline across all divisions.

• Crop science launched over 470 new seed products and 350 crop protection registrations in 2025.

• Pharma pipeline includes launches such as EYLEA 8mg and NUBEQA, with leading technology platforms.

• Consumer health maintains iconic brands and invests in start-ups through a strategic unit.